Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Stauber, RE; Kessler, HH.
Drugs in development for hepatitis C.
Drugs. 2008; 68(10): 1347-1359. Doi: 10.2165/00003495-200868100-00002
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Stauber Rudolf
Co-authors Med Uni Graz: Kessler Harald
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Currently available anti-hepatitis C virus (HCV) therapy is effective in only half of infected patients and is limited by adverse effects that often necessitate discontinuation. Therefore, new treatments are being developed, including optimization of current standard treatment with peginterferon plus ribavirin, specifically targeted antiviral therapy for HCV, novel immunomodulatory agents and treatments aimed at reducing fibrosis. This review focuses on novel anti-HCV drugs that are currently in an advanced stage of clinical development. Albinterferon-alpha-2b, a fusion molecule of albumin and interferon-alpha-2b, has a longer half-life than peginterferon, which enables a bi-weekly administration interval. Preliminary data indicate similar response rates for albinterferon-alpha-2b plus ribavirin compared with peginterferon-alpha-2b plus ribavirin, but possible benefits with respect to quality of life. Telaprevir, a NS3/4 protease inhibitor, demonstrated a rapid and profound antiviral effect in phase I trials that was synergistic with that of peginterferon-alpha-2a. Recently completed phase II trials on triple combination treatment with telaprevir, peginterferon-alpha-2a and ribavirin given for 12-24 weeks reported sustained virological response in up to 68% of patients with treatment-naive HCV genotype 1 infection.
Find related publications in this database (using NLM MeSH Indexing): Antiviral Agents - adverse effects; Clinical Trials as Topic -; Drug Delivery Systems -; Drug Design -; Hepatitis C - drug therapy; Humans -; Immunologic Factors - pharmacology; Liver Cirrhosis - drug therapy